Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy

BACKGROUND: Most lethal prostate cancers progress from relapse of aggressive primary disease. Recently, the most significant advances in survival benefit from systemic therapy have come from moving the administration of therapy to an earlier disease state. There is movement toward using biomarkers f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Urol Focus
Egile Nagusiak: VanderWeele, David J., Finney, Richard, Katayama, Kotoe, Gillard, Marc, Paner, Gladell, Imoto, Seiya, Yamaguchi, Rui, Wheeler, David, Lack, Justin, Cam, Maggie, Pontier, Andrea, Minh Nguyen, Yen Thi, Maejima, Kazuhiro, Sasaki-Oku, Aya, Nakano, Kaoru, Tanaka, Hiroko, Griend, Donald Vander, Kubo, Michiaki, Ratain, Mark J., Miyano, Satoru, Nakagawa, Hidewaki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586528/
https://ncbi.nlm.nih.gov/pubmed/29398457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euf.2018.01.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak